292 related articles for article (PubMed ID: 29627870)
1. Arterial Thrombosis in Patients with Cancer.
Tuzovic M; Herrmann J; Iliescu C; Marmagkiolis K; Ziaeian B; Yang EH
Curr Treat Options Cardiovasc Med; 2018 Apr; 20(5):40. PubMed ID: 29627870
[TBL] [Abstract][Full Text] [Related]
2. Arterial thrombosis and cancer.
Aronson D; Brenner B
Thromb Res; 2018 Apr; 164 Suppl 1():S23-S28. PubMed ID: 29703480
[TBL] [Abstract][Full Text] [Related]
3. Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational Study.
Bamias A; Tzannis K; Zakopoulou R; Sakellakis M; Dimitriadis J; Papatheodoridi A; Rallidis L; Halvatsiotis P; Tsiara A; Kaparelou M; Kostouros E; Barbarousi D; Koutsoukos K; Fragiadis E; Dellis AE; Anastasiou I; Stravodimos K; Pinitas A; Papatsoris A; Adamakis I; Varkarakis I; Fragoulis C; Pagoni S; Matsouka C; Skolarikos A; Mitropoulos D; Doumas K; Deliveliotis C; Constantinides C; Dimopoulos MA
Curr Oncol; 2022 Aug; 29(9):6077-6090. PubMed ID: 36135047
[TBL] [Abstract][Full Text] [Related]
4. Arterial Thrombosis in Cancer Patients: An Update.
Franchini M; Tufano A; Casoria A; Coppola A
Semin Thromb Hemost; 2021 Nov; 47(8):942-949. PubMed ID: 34464985
[TBL] [Abstract][Full Text] [Related]
5. Cancer-Associated Atherothrombosis: The Challenge.
Naschitz JE
Int J Angiol; 2021 Dec; 30(4):249-256. PubMed ID: 34853571
[TBL] [Abstract][Full Text] [Related]
6. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis.
Qi WX; Shen Z; Tang LN; Yao Y
Crit Rev Oncol Hematol; 2014 Nov; 92(2):71-82. PubMed ID: 24878433
[TBL] [Abstract][Full Text] [Related]
7. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics.
Sallah S; Wan JY; Nguyen NP
Thromb Haemost; 2002 Apr; 87(4):575-9. PubMed ID: 12008937
[TBL] [Abstract][Full Text] [Related]
8. Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review.
Solinas C; Saba L; Sganzerla P; Petrelli F
Thromb Res; 2020 Dec; 196():444-453. PubMed ID: 33065409
[TBL] [Abstract][Full Text] [Related]
9. Cancer and arterial thrombosis: therapeutic options.
Cheong MA; Leader A
Res Pract Thromb Haemost; 2024 Mar; 8(3):102393. PubMed ID: 38660456
[TBL] [Abstract][Full Text] [Related]
10. A Cohort Study of Incidences and Risk Factors for Thromboembolic Events in Patients with Idiopathic Membranous Nephropathy.
Zou PM; Li H; Cai JF; Chen ZJ; Li C; Xu P; Li MX; Chen LM; Li XM; Li XW
Chin Med Sci J; 2018 Jun; 33(2):91-99. PubMed ID: 29976278
[TBL] [Abstract][Full Text] [Related]
11. Thrombotic Complications Associated with Immune Checkpoint Inhibitors.
Wang TF; Khorana AA; Carrier M
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572833
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapeutic Agents and the Risk of Ischemia and Arterial Thrombosis.
Hassan SA; Palaskas N; Kim P; Iliescu C; Lopez-Mattei J; Mouhayar E; Mougdil R; Thompson K; Banchs J; Yusuf SW
Curr Atheroscler Rep; 2018 Feb; 20(2):10. PubMed ID: 29423705
[TBL] [Abstract][Full Text] [Related]
13. Assessing the risk of thromboembolism in cancer patients receiving immunotherapy.
Goel A; Khorana A; Kartika T; Gowda S; Tao DL; Thawani R; Shatzel JJ
Eur J Haematol; 2022 Apr; 108(4):271-277. PubMed ID: 34905252
[TBL] [Abstract][Full Text] [Related]
14. Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies.
Moik F; Ay C
Thromb Res; 2022 May; 213 Suppl 1():S58-S65. PubMed ID: 36210562
[TBL] [Abstract][Full Text] [Related]
15. Risk of venous and arterial thromboembolic events associated with tyrosine kinase inhibitors in advanced thyroid cancer: a meta-analysis and systematic review.
Bai Y; Li JY; Li J; Zhang B; Liu YH; Zhang BY; Jing J
Oncotarget; 2019 Jun; 10(41):4205-4212. PubMed ID: 31289618
[No Abstract] [Full Text] [Related]
16. Low-molecular-weight heparin and calcium heparin in thrombosis prophylaxis in patients with percutaneous arterial and venous ports for colorectal liver metastases.
Zanon C; Bortolini M; Chiappino I
Tumori; 2005; 91(6):477-80. PubMed ID: 16457145
[TBL] [Abstract][Full Text] [Related]
17. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Scappaticci FA; Skillings JR; Holden SN; Gerber HP; Miller K; Kabbinavar F; Bergsland E; Ngai J; Holmgren E; Wang J; Hurwitz H
J Natl Cancer Inst; 2007 Aug; 99(16):1232-9. PubMed ID: 17686822
[TBL] [Abstract][Full Text] [Related]
18. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR
Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
[TBL] [Abstract][Full Text] [Related]
19. Thrombosis in hematological malignancies: mechanisms and implications.
Horowitz NA; Brenner B
Thromb Res; 2020 Jul; 191 Suppl 1():S58-S62. PubMed ID: 32736780
[TBL] [Abstract][Full Text] [Related]
20. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
